ZIM Labs’ Dr. Nidhi Sapkal to address CPhI Worldwide at Germany

Principal Research Coordinator at ZIM Labs, Dr. Nidhi Sapkal will be sharing ZIM's experience on challenges faced during technology development of thin films at CPhI Worldwide at Messe Frankfurt, Germany from October 24th to 26th. ZIM has proprietary technology for developing thin film based products named as Thinoral®. ZIM has already developed over 30 products based on Thinoral® technology. Dr. Nidhi Sapkal will be addressing the gathering of learned pharmacists and companies on the topic ‘Oral Thin Films: Innovative Dosage Form for Improving Patient Compliance’. The Thinoral technology is used to manufacture fast dissolving thin films that are instantly wettable, non-sticky, non-tacky and non-curving. They’re easy to consume and hence contribute to patient convenience and adherence. ZIM has received IPA-ACG-Scitech Award for Best Innovation in solid dosage form, December ‘16 for Thinoral®. 

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 42,000 visiting pharma professionals over three days. 2,500+ exhibitors from 153 countries gather at the event to network and take advantage of more than 150 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in Frankfurt.

About ZIM Labs

ZIM Laboratories Limited is an innovative drug delivery solutions providing company targeting patient convenience and adherence. It uses proprietary technologies (modified release and taste masking), to develop and manufacture differentiated pharmaceutical products.

It is located in Nagpur, Central India and is EU-GMP, WHO-GMP Certified and ISO 9001:2008 accredited company supported by an excellent team of professionals and state-of- the-art facility.

ZIM is engaged in the activities of research and development, manufacturing, distribution and marketing of oral solid dosage formulations and pre-formulations (PFI) covering tablets, capsules, dry syrups, pellets, granules and orally disintegrating strips (ODS). More information available on ZIM

Comments

Post a Comment

Popular posts from this blog

The Financial World: ZIM Laboratories Limited Listing on BSE Main Board

ZIM Laboratories Limited (ZIM) has been listed on the BSE Main Board on June 8, 2018. The book value price of ZIM was Rs 160 per equity share. Anwar Daud, Chairman & Managing Director, told media persons here recently that ZIM is amongst the few global companies to have developed and commercialized the oral film technology, besides also being the first Indian company to manufacture multi-layer thin films that contain more than one API on a single thin strip. Describing ZIM Laboratories as a unique R&D-centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS), he said ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines and the company listing on BSE on June 8 had a price discovery as per trading on the bourses. Original Article
Read more

ZIM’s exclusive Oral Thin Film manufacturing technology - ‘Thinoral®’

Image
Fast dissolving oral films are thin & elegant films that dissolves instantaneously when kept on the tongue. These films do not require water for their administration. The films are instantly wettable, rapidly dissolving, non-sticky, non-tacky, and non-curving. As much as 100 mg of active drug can be loaded on these films. A patent application has already been filed in various countries. The technology has been registered with the name ‘ Thinoral ® ’. It is suitable for delivery of thermo labile actives, also both solid and liquid drugs can be formulated into thin film delivery platform.The dosage form is ideal for special need patient population segment. There are many patients who can’t swallow their medicines. ZIM has so far developed about 30 products in Orally Disintegrating Films dosage form and many more are in pipeline. About ZIM Labs ZIM Laboratories Limited is an innovative drug delivery solutions providing company targeting patient convenience and adheren
Read more

APN News: ZIM Laboratories Limited to List on BSE Main Board on June 8, 2018

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries. Original Article  
Read more